Search

Your search keyword '"Eric Jonasch"' showing total 546 results

Search Constraints

Start Over You searched for: Author "Eric Jonasch" Remove constraint Author: "Eric Jonasch"
546 results on '"Eric Jonasch"'

Search Results

1. Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States

2. 523 Nivolumab and ipilimumab in patients with metastatic non-clear cell renal cell carcinoma at MD Anderson Cancer Center

Catalog

Books, media, physical & digital resources

3. 718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

4. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy

5. The glycoprotein CD147 defines miRNA‐enriched extracellular vesicles that derive from cancer cells

6. Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries

7. Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma

8. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma

9. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

10. Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL

11. Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes

12. Response to correspondence on 'Reproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluation'

13. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma

14. VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent Actions

15. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

16. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

17. Reproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluation

18. Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

19. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials

20. AKT isoform-specific expression and activation across cancer lineages

21. BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation

22. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening

23. Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma

24. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

25. Cadherin-11 in renal cell carcinoma bone metastasis.

26. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.

28. Bioinformatics Strategies for Identifying Regions of Epigenetic Deregulation Associated with Aberrant Transcript Splicing and RNA-editing.

29. Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects

30. Data from Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling

31. Supplementary Figure Legends from Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras–ERK Pathway Activation in Hypoxia

32. Supplementary Table from Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling

33. Data from Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras–ERK Pathway Activation in Hypoxia

35. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma

36. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

37. CCR Translation for This Article from Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients

38. Supplementary Figure legends from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

39. Data from HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas

40. Supplementary Table 3 from Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas

41. Supplementary Table 1 from Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas

42. Supplementary Figure 2 from Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas

43. Supplementary Figure 5 from Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas

45. Supplementary Methods from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

46. Supplementary Figure 4 from Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas

47. Supplementary Data from Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer

48. Supplementary Fig. 6 from HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas

49. Supplementary Fig. 2 from HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas

50. Supplementary Figure 6 from Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas